ATH 0.00% 2.3¢ alterity therapeutics limited

wow look at this

  1. 3,680 Posts.
    lightbulb Created with Sketch. 137,25197,23314816-25658,00.html
    "Johnson & Johnson & Prana

    NOW that Prana Biotechnology shares have succumbed to gravity, investors must be wondering what's next for the aspiring drug developer?

    The company's share price soared 54 per cent last week following news that its potential Alzheimer's disease drug had passed a 12-week safety trial with flying colours, showing some modest but encouraging signs of efficacy. After three days of above-average trading volumes, it is now back to previous levels.

    However, it appears that there might be more good news to come.

    The Melbourne-based drug developer recently played host to a team of executives from global healthcare giant Johnson & Johnson. And it wasn't just a social call.

    The visitors spent some time poring over Prana's books, including data on its drug, known as PBT2.

    While Prana chairman Geoffrey Kempler remains tight-lipped, it is believed confidentiality agreements have been signed and the companies are in the throes of nutting out a licensing deal that would see the pharmaceutical company fund further trials."

    And from J&Js website, looks like they do more than baby powder.

    "Reporting directly to the worldwide chairman of pharmaceuticals, the pharmaceuticals licensing and acquisitions team identifies, negotiates and executes opportunities for the entire pharmaceuticals business. Comprised mostly of medical doctors and Ph.D. scientists, this team helps potential partners identify and work with the Johnson & Johnson business unit most likely to be interested in a specific project. The team also has established an alliance management organization to ensure healthy long-term relationships with partners.

    Our pharmaceutical companies approach each partnering situation as a unique opportunity. Our business development specialists avoid standardized deals. They focus on the success of the products and the long-term goals of both partners. Licensing and acquisitions specialists secure support from senior management early in the process and deploy a strong cross-functional team to help ensure all licensing agreements can be closed within three to six months. Once transactions are completed, business development professionals at the operating company level integrate the new technology or product into the Johnson & Johnson company's portfolio."
    With his little leak perhaps ELAN will have to make a move if they intend to.
    With a market cap of 179 Billiom JNJ could fund PBTs trials with their pin money.

watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Mkt cap ! $20.07M
Open High Low Value Volume
2.2¢ 2.3¢ 2.2¢ $5.749K 251.3K

Buyers (Bids)

No. Vol. Price($)
3 244430 2.2¢

Sellers (Offers)

Price($) Vol. No.
2.6¢ 144455 1
View Market Depth
Last trade - 15.26pm 10/12/2019 (20 minute delay) ?
0.000 ( 0.00 %)
Open High Low Volume
2.3¢ 2.3¢ 2.3¢ 80172
Last updated 10.30am 10/12/2019 (live) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.